Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00548821|
Recruitment Status : Unknown
Verified May 2008 by National University Hospital, Singapore.
Recruitment status was: Not yet recruiting
First Posted : October 24, 2007
Last Update Posted : May 15, 2008
|Condition or disease||Intervention/treatment||Phase|
|Locally Advanced Cervical Cancer||Drug: Cisplatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer|
ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
- The primary aim of this research protocol is to compare if there is a difference in progression free survival between weekly versus 5-day 3 weekly cisplatin based chemotherapy regimen in women with locally advanced cervical cancer.
- The secondary aims are to compare quality of life assessment of patients and their carers as well as toxicity profiles both acute and late.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00548821
|Contact: Johann Tang||677204870||Johann_Tang@mail.nhg.com.sg|
|National University Hospital||Not yet recruiting|
|Singapore, Singapore, 119074|
|Principal Investigator:||Johann Tang||NUH|